Navigation Links
Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA)
Date:7/24/2014

orward to working with our partner PharmaEssentia to initiate the clinical trials of KX2-391 Ointment for psoriasis, and oral KX2-391 for leukemia and other oncology indications."

About Kinex:

Kinex Pharmaceuticals is a Buffalo, New York based company with additional offices in Cranford, New Jersey, Taipei, Taiwan and Hong Kong.  In addition to KX2-391 Ointment, the Company has four oral oncology drugs currently in clinical stages of development.  Two programs have emerged from collaboration with Hanmi Pharmaceuticals on the Orascovery Platform including Oraxol (oral paclitaxel) and Oratecan (oral irinotecan). Internally discovered compounds include KX2-391 for oncology indications and KX2-361 for glioma which was also been granted orphan drug designation.

Kinex is developing its pipeline globally through partnerships with: Hanmi Pharmaceuticals (Seoul, Korea), Xiangxue Pharmaceuticals (Guangzhou, China), PharmaEssentia Corporation (Taipei, Taiwan) and Zenith Technology (Dunedin, New Zealand). Kinex is also working on additional Orascovery-based drug candidates in collaboration with Hanmi Pharmaceuticals and some of the projects received research funding support from the Innovation and Technology Commission (ITC) of the Government of the Hong Kong Special Administrative Region through Kinex Pharmaceuticals (HK) Limited* and the support of the Department of Applied Biology and Chemical Technology of the Hong Kong PolyTechnic University.

*Any opinions, findings, conclusions or recommendations expressed in this material do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Innovation and Technology Commission or the Small Entrepreneur Research Assistance Programme Project Assessment Panel.

Website:
'/>"/>

SOURCE Kinex Pharmaceuticals
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kinex Pharmaceuticals Announced that the U.S. Food and Drug Administration has Granted Orphan Drug Status to KX02 for the Treatment of Gliomas
2. Kinex Announces First Patient Dosed in Phase Ib Study of Oraxol, an Orally Dosed Paclitaxel
3. Hanmi Pharmaceuticals to Assign the Rights to Five New Territories to Kinex as Part of the Orascovery Program Strategic Plan
4. Dr. David Hangauer, Chief Scientific Officer and Co-Founder, commits his career to Kinex Pharmaceuticals
5. Kinex Receives Research Support from the Hong Kong Innovation and Technology Commission (ITC)
6. Kinex Announces that the US FDA Allows their IND for Oraxol, an Oral Form of Paclitaxel that is in Phase II Clinical Trials in Korea, to Begin Clinical Trials in the US
7. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
8. Kinex Announces that the US FDA Allows their IND to Begin KX02 Clinical Trials
9. Kinex Pharmaceuticals and Zenith Technology Corporation announce the execution of a collaborative licensing agreement
10. Kinex Pharmaceuticals Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Societys 2013 Honoree for its Cuisine for a Cure event
11. Hanmi and Kinex Announced Korean FDA Allowance of the KX01 IND Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Denmark and ATLANTA , August ... the US Food and Drug Administration (FDA) cleared the MagVita ... in adult patients who have failed to receive satisfactory improvement ... a non-invasive technique for stimulating neural tissue in the part ... Disorder. The procedure has been proven safe and effective and ...
(Date:8/28/2015)... LONDON , August 28, 2015 ... approach seamlessly connects people, technologies and care ... improving outcomes and the cost of healthcare delivery ... AEX: PHIA) today announced its presence at  ESC Congress 2015 , ... Heart Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect ...
(Date:8/27/2015)... -- Biosimilars are not generics and the Biologics ... Drug Administration (FDA) for recognizing that each biosimilar ... issued today. The FDA,s draft guidance on nonproprietary ... for biological products to bear a nonproprietary name ... the agency,s thinking that "there is a need ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... Ontario, July 18, 2011 CardioGenics Holdings Inc. (CGNH.OB) ... available for on-demand viewing at the RetailInvestorConferences website. ... will be available 24/7 for 90 days. Investors may ... the next three weeks. About CardioGenics ...
... July 18, 2011 Coronado Biosciences, Inc. (the "Company"), ... immunotherapy agents for the treatment of autoimmune diseases and ... on Form 10 with the Securities and Exchange Commission ... the purpose of becoming a reporting company.  The filing ...
Cached Medicine Technology:CardioGenics Holdings Inc. Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com 2Coronado Biosciences Files to Become a Public Reporting Company 2
(Date:8/29/2015)... Raleigh, NC (PRWEB) , ... August 29, 2015 ... ... about how mesothelioma develops, may extend and improve the lives of patients, according ... its website. Click here to read the full article. , The ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , ... standard shipping costs. , “Before, a threshold of $49.00 was required to qualify for ... items qualify for free standard shipping for customers regardless of the item’s selling price.” ...
(Date:8/29/2015)... ... 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops designed for ... unique footage that users can shrink and stretch in the Final Cut Pro X ... customize color, brightness, scale, speed, range, and flare attributes with intuitive controls found in ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
(Date:8/29/2015)... TX (PRWEB) , ... August 29, 2015 , ... ... allows the company to freely market and sell Arterosil and Arterosil HP, and ... Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the United ...
Breaking Medicine News(10 mins):Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... A study in the New England Journal of Medicine ... of lung cancer are responding positively to a treatment that ... shows 57 percent of patients with ALK-positive advanced non-small cell ... crizotinib, an investigational anaplastic lymphoma kinase (ALK) inhibitor. In some ...
... Beta cells, which make insulin in the human body, do ... may be closer to better treating diabetes. Type 1 ... auto-immunity while type 2 is due to a relative insufficiency ... remained an open issue, and is critically important for designing ...
... -- The rate of new cases of end-stage kidney disease ... between 1996 and 2007, a new study has found. ... end-stage renal disease (ESRD), that was linked to diabetes declined ... time. The declining rates occurred in all regions and in ...
... the immune system and nervous system turn Neuroimmunology into ... Between October 26th and 30th takes place in Sitges ... the International Society of Neuroimmunology. This event highlights the ... to new technologies, but also highlights the long road ...
... Commonwealth University Massey Cancer Center recently was awarded ... Tobacco Indemnification and Community Revitalization Commission (Tobacco Commission) ... involvement and to grow its state-of-the-art clinical research ... is already in place in communities across Virginia, ...
... (HealthDay News) -- Two-thirds of preschoolers in the United ... hours per day of screen time from television, computers, ... of Pediatrics, a new study has found. Researchers ... Washington looked at the daily screen time of nearly ...
Cached Medicine News:Health News:People with specific kind of lung cancer respond to new targeted treatment 2Health News:People with specific kind of lung cancer respond to new targeted treatment 3Health News:Insulin-creating cell research may lead to better diabetes treatment 2Health News:Drop Seen in Rate of End-Stage Kidney Disease in Diabetics 2Health News:Multiple sclerosis will become a controlled disease like AIDS 2Health News:VCU Massey Cancer Center awarded $2.4 million grant from Virginia Tobacco Commission 2Health News:U.S. Preschoolers Getting Too Much Screen Time: Study 2
... A stethoscope adapter for users of ... acrylic shell type., ,Impressions of ... ,Westone custom products for the ear ... of hearing healthcare providers. These providers ...
Advanced architecture. Small, lightweight and compact. Easy to use....
... bronchoscopy: The HF-compatible V series from Pentax, ... bronchoscopes are measured., ,The HF-compatible series ... FB-19TV, FB-18V and FB-15V models along with ... FB-8V, offer much better image quality thanks ...
... benefits of fibre bronchoscopy: The HF-compatible V ... all other fibre bronchoscopes are measured., ... PENTAX, including the FB-19TV, FB-18V and FB-15V ... and the pediatric FB-8V, offer much better ...
Medicine Products: